| Literature DB >> 30368237 |
Muhammad Tahir Ul Qamar1, Amna Bari2, Muhammad Muzammal Adeel1, Arooma Maryam3, Usman Ali Ashfaq4, Xiaoyong Du1,5, Iqra Muneer6, Hafiz Ishfaq Ahmad5, Jia Wang7,8.
Abstract
BACKGROUND: Chikungunya virus (CHIKV), causes massive outbreaks of chikungunya infection in several regions of Asia, Africa and Central/South America. Being positive sense RNA virus, CHIKV replication within the host resulting in its genome mutation and led to difficulties in creation of vaccine, drugs and treatment strategies. Vector control strategy has been a gold standard to combat spreading of CHIKV infection, but to eradicate a species from the face of earth is not an easy task. Therefore, alongside vector control, there is a dire need to prevent the infection through vaccine as well as through antiviral strategies.Entities:
Keywords: B cell and T cell epitopes; Chikungunya virus (CHIKV); Computational approaches; Vaccine
Mesh:
Substances:
Year: 2018 PMID: 30368237 PMCID: PMC6204282 DOI: 10.1186/s12967-018-1672-7
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
B cell epitopes predicted through BCPRED
| Serial no | Position | Peptide sequence | BCPRED score | Vaxigen score |
|---|---|---|---|---|
| 1 |
|
|
|
|
| 2 | 203 | IPTGAGKPGDSGRP | 0.999 | 1.1666 |
| 3 | 1198 | NYPASHTTLGVQDI | 0.973 | 1.2162 |
| 4 | 453 | PFHHDPPVIGREKF | 0.97 | 0.8542 |
| 5 | 412 | TSAPCTITGTMGHF | 0.92 | 0.9881 |
| 6 | 723 | TPYELTPGATVPFL | 0.858 | 0.9848 |
| 7 | 183 | PEGYYNWHHGAVQY | 0.745 | 0.9042 |
| 8 | 1052 | WLKERGASLQHTAP | 0.711 | 1.1089 |
Fig. 1a Prediction of antigenic determinants using Kolaskar and Tongaonkar antigenicity scale, b hydrophilicity prediction using Parker hydrophilicity, c surface accessibility analyses using Emini surface accessibility scale, d beta turns analyses in structural polyprotein using Chou and Fasman beta turn prediction, e flexibility analyses using Karplus and Schulz flexibility scale
Discontinuous epitopes predicted via DISCO TOP 2.0 by using three-dimensional structure
| Serial no | Position | Residue | Contact no. | Disco tope score |
|---|---|---|---|---|
| 1 | 147 | HIS | 0 | 4.499 |
| 2 | 269 | PRO | 15 | 3.228 |
| 3 | 273 | ASN | 6 | 3.193 |
| 4 | 290 | ASP | 9 | 4.196 |
| 5 | 291 | HIS | 18 | 2.951 |
| 6 | 292 | PRO | 10 | 3.122 |
| 7 | 312 | MET | 0 | 3.904 |
Fig. 2Site of predicted epitopes on chains of the crystal structure of CHIKV structural polyprotein highlighted through cartoon representation
MHC class I peptides predicted through propred-I with their alleles and antigenicity scores
| Serial no | Peptide | MHC class I alleles | Score |
|---|---|---|---|
| 1 | IFDNKGRVVAIVL | HLA-B*3501. HLA-B*3701, HLA-B*5101, HLA-B*5103, HLA-B*5201, HLA-B*51, HLA-Cw*0401, MHC-Kd | 1.106 |
| 2 | PLVPRNAEL | HLA-A2, HLA-A2.1, HLA-B8, HLA-Cw*0301 | 1.3876 |
| 3 | VMHKKEVVL | HLA-A2, HLA-A*0201, HLA-A*0205, HLA-A3, HLA-A2.1, HLA-B*2702, HLA-B*2705, HLA-B*3902, HLA-B*5301, HLA-B*51, HLA-B7, HLA-B*0702, HLA-B8, HLA-Cw*0401, MHC-Dd | 1.0207 |
| 4 | LSVTLEPTL | HLA-A24, HLA-A2.1, HLA-B*3501, HLA-B*3902, HLA-B40, HLA-B*5301, HLA-B*51, HLA-B*5801, HLA-B60, HLA-B7, HLA-Cw*0301, HLA-Cw*0602, MHC-Db, MHC-Db revised, MHC-Kd, MHC-Ld | 1.3989 |
| 5 |
|
|
|
| 6 | GTLKIQVSL | HLA-A2, HLA-A*0205, HLA-B14, HLA-B*3701, HLA-B40, HLA-B*5801, HLA-B7, HLA-Cw*0301, HLA-Cw*0602, MHC-Db, MHC-Db revised, MHC-Kd | 0.5303 |
| 7 | LQISFSTAL | HLA-A2, HLA-A*0201, HLA-A*0205, HLA-A2.1, HLA-B14, HLA-B*2702, HLA-B*2705, HLA-B*3902. HLA-B40, HLA-B*5201, HLA-B*5301, HLA-B*51, HLA-B60, HLA-B62, HLA-B7, HLA-Cw*0301, HLA-Cw*0602, MHC-Db revised, MHC-Kd | 0.6264 |
T cell epitopes against MHC class II alleles through propred
| Serial no | Peptide | MHC class II alleles | Score |
|---|---|---|---|
| 1 | FKRSSKYDL | DRB1_0305, DRB1_0309, DRB1_0701, DRB1_0703, DRB1_1114, DRB1_1120, DRB1_1302, DRB1_1323, DRB5_0101, DRB5_0105 | 1.054 |
| 2 | LLANTTFPC | DRB1_0401, DRB1_0402, DRB1_0404, DRB1_0405, DRB1_0408, DRB1_0410, DRB1_0421, DRB1_0423, DRB1_0426, DRB1_1102, DRB1_1107, DRB1_1114, DRB1_1121, DRB1_1322, DRB1_1323 | 1.0945 |
| 3 | LKIQVSLQI | DRB1_0101, DRB1_0402, DRB1_0404, DRB1_0405, DRB1_0408, DRB1_0410, DRB1_1101, DRB1_1102, DRB1_1104, DRB1_1106, DRB1_1114, DRB1_1120, DRB1_1121, DRB1_1128, DRB1_1301, DRB1_1302, DRB1_1305, DRB1_1311, DRB1_1321, DRB1_1322, DRB1_1323, DRB1_1327, DRB1_1328, DRB1_1501, DRB1_1502, DRB1_1506 | 0.9054 |
| 4 | FVRTSAPCTI | DRB1_0101, DRB1_0102, DRB1_0421, DRB1_0426, | 1.0082 |
| 5 | VGFTDSRKI | DRB1_0402, DRB1_0701, DRB1_0703, DRB5_0101, DRB5_0105 | 1.0491 |
| 6 |
|
| |
| 7 | WVMHKKEVV | DRB1_0301, DRB1_0305, DRB1_0306, DRB1_0307, DRB1_0308, DRB1_0309, DRB1_0311, DRB1_0813, DRB1_1101, DRB1_1102, DRB1_1107, DRB1_1114, DRB1_1120, DRB1_1121, DRB1_1128, DRB1_1301, DRB1_1302, DRB1_1304, DRB1_1305, DRB1_1307, DRB1_1321, DRB1_1322, DRB1_1323, DRB1_1327, DRB1_1328, DRB1_1502 | 1.0706 |
| 8 | LVVAVAALILIVVLCVSFSR | DRB1_0301, DRB1_0402, DRB1_1102, DRB1_1107, DRB1_1121, DRB1_1301, DRB1_1322, DRB1_1323, DRB1_1327, DRB1_1328, DRB5_0101, DRB5_0105 | 0.909 |
Fig. 3Phylogenetic tree illustrating the evolutionary conserveness of CHIKV strains form 23 countries
Docking results predicted through molecular operating environment by using three-dimensional structure of peptides against HLA-B7
| Serial no | Peptide | Docking score | Interacting residues |
|---|---|---|---|
| 1 | VMHKKEVVL | − 20.2086 | Lys-243, Glu-232, Tyr-26, Tyr63, Thr-233, Thr-10 |
| 2 | GTLKIQVSL | − 19.6688 | Ser-4, Arg-6, Thr-31, Asp102, Gln-32 |
| 3 | LSVTLEPTL | − 17.3569 | His-3, Thr-31, Asp-102, Glu-180 |
| 4 | LQISFSTAL | − 14.5594 | Arg-6, Glu-232, Thr-31 |
Fig. 4a Graphical representation of human HLA-B7 allele (shown in cyan and purple) with bound peptide 1 “VMHKKEVVL” (yellow). Multiple residues of the receptor protein (green) interact (dotted lines) with the peptide residues (red). b LigX interaction diagram illustrating the chain A and chains B residues interacting via hydrogen bond (green), two water mediated interaction (yellow), vanderval interaction (blue) to the peptide 1
Fig. 5a Graphical representation of human HLA-B7 allele (shown in cyan and purple) with bound peptide 2 “GTLKIQVSL” (blue). Multiple residues of the receptor protein (green) interact (dotted lines) with the peptide residues (red). b LigX interaction diagram illustrating the chain A residues interacting via hydrogen bond (green), one water mediated interaction (yellow), vanderval interaction (blue) to the peptide 2
Fig. 6a Graphical representation of human HLA-B7 allele (shown in cyan and purple) with bound peptide 3 (yellow). Multiple residues of the receptor protein (green) interact (dotted lines) with the peptide residues (red). b LigX interaction diagram illustrating the chain A residues interacting via hydrogen bond (green) and vanderval interaction (blue) to the peptide 3
Fig. 7a Graphical representation of human HLA-B7 allele (shown in cyan and purple) with bound peptide 4 (black). Multiple residues of the receptor protein (green) interact (dotted lines) with the peptide residues (red). b LigX interaction diagram illustrating the chain A residues interacting via hydrogen bond (green) and vanderval interaction (blue) to the peptide 4